Probiotics administered intravaginally as a complementary therapy combined with antibiotics for the treatment of bacterial vaginosis: a systematic review protocol

Liyan Ma, Jianrong Su, Yanli Su, Wei Sun, Zhaoying Zeng, Liyan Ma, Jianrong Su, Yanli Su, Wei Sun, Zhaoying Zeng

Abstract

Introduction: Bacterial vaginosis (BV) is a highly prevalent vaginal polymicrobial disorder commonly encountered in women of childbearing age. Therapy with only recommended antibiotics results in low cure rates and unacceptably high recurrence rates. The use of probiotics as a complementary approach for use with antibiotics for the treatment of BV remains unclear. This review aims to assess the efficacy of lactobacilli administered intravaginally in conjunction with antibiotics for the treatment of BV.

Methods and analysis: The Cochrane Central Register of Controlled Trials in The Cochrane Library, Cochrane Library of Systematic Reviews, Medline/PubMed and Embase will be used to search for articles from database inception to November 2016. Randomised controlled clinical trials using lactobacilli administered intravaginally in conjunction with antibiotics to treat BV will be included. Primary outcome will be the BV cure rate. The recurrence rate will be examined as secondary outcome. Two reviewers will independently select trials and extract data from the original publications. The risk of bias will be assessed according to the Cochrane Risk of Bias tool. We will perform data synthesis using the Review Manager (RevMan) software V.5.2.3. To assess heterogeneity, we will compute the I2 statistic.

Ethics and dissemination: This study will be a review of published data and it is not necessary to obtain ethical approval. Findings of this systematic review will be published in a peer-reviewed journal.

Trial registration number: International Prospective Register of Systematic Reviews 2014: CRD42014015079.

Keywords: bacteriology; genitourinary medicine; microbiology; urogynaecology.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
Flow diagram of the search for eligible studies on the probiotics administered intravaginally as a complementary therapy in combination with antibiotics for the treatment of bacterial vaginosis. CENTRAL, Cochrane Central Register of Controlled Trials; STI, sexually transmitted infection.

References

    1. Walker J, Hocking JS, Fairley CK, et al. . The prevalence and incidence of bacterial vaginosis in a cohort of young Australian women In:Conference proceedings of the International Society for Sexually Transmitted Diseases Research Quebec, Canada, 2011.
    1. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. Am J Obstet Gynecol 2013;209:505–23. 10.1016/j.ajog.2013.05.006
    1. Dingens AS, Fairfortune TS, Reed S, et al. . Bacterial vaginosis and adverse outcomes among full-term infants: a cohort study. BMC Pregnancy Childbirth 2016;16:278–86. 10.1186/s12884-016-1073-y
    1. Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2007;21:375–90. 10.1016/j.bpobgyn.2006.12.005
    1. Cohen CR, Lingappa JR, Baeten JM, et al. . Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med 2012;9:e1001251 10.1371/journal.pmed.1001251
    1. Haggerty CL, Totten PA, Tang G, et al. . Identification of novel microbes associated with pelvic inflammatory disease and infertility. Sex Transm Infect 2016;92:441–6. 10.1136/sextrans-2015-052285
    1. Atashili J, Poole C, Ndumbe PM, et al. . Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 2008;22:1493–501. 10.1097/QAD.0b013e3283021a37
    1. Lamont RF, Sobel JD, Akins RA, et al. . The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG 2011;118:533–49. 10.1111/j.1471-0528.2010.02840.x
    1. Li J, McCormick J, Bocking A, et al. . Importance of vaginal microbes in reproductive health. Reprod Sci 2012;19:235–42. 10.1177/1933719111418379
    1. Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst Rev 2009;3:CD006055 10.1002/14651858.CD006055.pub2
    1. Hay P. Recurrent bacterial vaginosis. Curr Opin Infect Dis 2009;22:82–6. 10.1097/QCO.0b013e32832180c6
    1. Bradshaw CS, Morton AN, Hocking J, et al. . High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006;193:1478–86. 10.1086/503780
    1. Tomusiak A, Strus M, Heczko PB. Antibiotic resistance of Gardnerella vaginalis isolated from cases of bacterial vaginosis. Ginekol Pol 2011;82:900–4.
    1. Stapleton AE, Au-Yeung M, Hooton TM, et al. . Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis 2011;52:1212–7. 10.1093/cid/cir183
    1. Hempel S, Newberry SJ, Maher AR, et al. . Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012;307:1959–69. 10.1001/jama.2012.3507
    1. Su J, Ma L, Yan D, et al. . An E. coli strain and its preparation method used to treat intestinal microflora disorders. National invention patent; (2012), patent number: 2012ZL201110117270.7.
    1. Tomusiak A, Strus M, Heczko PB, et al. . Efficacy and safety of a vaginal medicinal product containing three strains of probiotic bacteria: a multicenter, randomized, double-blind, and placebo-controlled trial. Drug Des Devel Ther 2015;9:5345–54. 10.2147/DDDT.S89214
    1. Ya W, Reifer C, Miller LE. Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study. Am J Obstet Gynecol 2010;203:e1–e6. 10.1016/j.ajog.2010.05.023
    1. Mastromarino P, Vitali B, Mosca L. Bacterial vaginosis: a review on clinical trials with probiotics. New Microbiol 2013;36:229–38.
    1. Huang H, Song L, Zhao W. Effects of probiotics for the treatment of bacterial vaginosis in adult women: a meta-analysis of randomized clinical trials. Arch Gynecol Obstet 2013;289:1225–34. 10.1007/s00404-013-3117-0
    1. Falagas M, Betsi GI, Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol Infect 2007;13:657–64. 10.1111/j.1469-0691.2007.01688.x
    1. Senok AC, Verstraelen H, Temmerman M, et al. . Probiotics for the treatment of bacterial vaginosis. Cochrane DB Syst Rev; (2009):CD006289.
    1. Moher D, Liberati A, Tetzlaff J, et al. . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535 10.1136/bmj.b2535
    1. Forsum U, Hallén A, Larsson PG. Bacterial vaginosis-a laboratory and clinical diagnostics enigma. APMIS 2005;113:153–61. 10.1111/j.1600-0463.2005.apm1130301.x
    1. Egger M, Davey Smith G, Schneider M, et al. . Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34. 10.1136/bmj.315.7109.629
    1. Balshem H, Helfand M, Schünemann HJ, et al. . GRADE guidelines: rating the quality of evidence. J Clin Epidemiol 2011;64:401–6. 10.1016/j.jclinepi.2010.07.015

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner